Related Experiment Video

Updated: Jan 14, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.6K

Community-acquired pneumonia

Luis Felipe Reyes1, Andrew Conway Morris2, Cristian Serrano-Mayorga3

  • 1Unisabana Center for Translational Science, School of Medicine, Universidad de La Sabana, Chía, Colombia; Clinica Universidad de La Sabana, Chía, Colombia; International Severe Acute Respiratory and Emerging Infection Consortium, Pandemic Sciences Institute, University of Oxford, Oxford, UK.

Lancet (London, England)
|October 19, 2025
PubMed

Insights

Community-acquired pneumonia (CAP) poses a global health threat with long-term complications. Advances in diagnostics and personalized treatments, including nucleic acid amplification tests (NAATs), offer improved outcomes for CAP management.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Public Health

Background:

  • Community-acquired pneumonia (CAP) is a significant global health issue, particularly impacting vulnerable groups.
  • Previously viewed as acute, CAP is now understood to have long-term consequences like cardiovascular events and cognitive decline.

Purpose of the Study:

  • To review current understanding and future directions in CAP management.
  • To highlight the evolving role of diagnostics and personalized therapies in combating CAP.

Main Methods:

  • Literature review focusing on recent advancements in CAP diagnostics and treatment.
  • Analysis of the integration of new technologies like nucleic acid amplification tests (NAATs) and lung ultrasound.
  • Evaluation of the role of adjunctive therapies and preventive strategies.

Main Results:

  • Nucleic acid amplification tests (NAATs) and point-of-care lung ultrasound enable rapid pathogen detection and tailored treatment.
  • Uncertainties persist regarding the clinical utility of NAATs, lung ultrasounds, and serum biomarkers.
  • The roles of adjunctive therapies like corticosteroids and immunomodulators require further definition.

Conclusions:

  • Comprehensive CAP management necessitates personalized treatment, post-acute rehabilitation, and cardiovascular screening.
  • Integrating advanced diagnostics and tailored therapies is crucial for improving outcomes and reducing the global burden of CAP.
  • Strengthening preventive measures, such as vaccination, remains essential.

More Related Videos

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

23.7K
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.5K

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
723
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
777
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
2.6K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
751
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.4K
Acute Pyelonephritis I: Introduction01:27

Acute Pyelonephritis I: Introduction

Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such...
475